Latest Sdi (ASX:SDI) News

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.

SDI Limited reported a modest 2% dip in net profit for H1 FY26 despite a 2.7% rise in sales, driven by growth in aesthetics and exports. The company faces challenges from regulatory bans on Amalgam products while advancing plans for manufacturing upgrades and a potential acquisition.

SDI Limited reported stable FY25 revenue with improved margins and advancing Montrose project, while regional sales showed mixed results.

SDI Limited reported a steady FY2025 with a slight profit increase, driven by growth in aesthetic and whitening products and the launch of its new amalgam replacement, Stela. The company also announced plans for a new factory to boost production capacity.

SDI Limited’s FY25 results reveal steady revenue with improved margins driven by operational efficiencies and strong European and Brazilian sales. The company is progressing its Montrose facility project and advancing ESG initiatives.

SDI Limited reported a 16.7% rise in net profit after tax for FY2025, driven by improved gross margins and operational efficiencies despite a slight sales dip. The company maintained its dividend while investing in automation and new product development.

SDI Limited reported a 16.7% rise in net profit to $12.2 million for FY2025, maintaining dividends amid mixed regional sales and margin gains. The company plans significant production automation and facility redevelopment to drive future growth.

SDI Limited reports a flat sales performance for FY25 with regional growth offset by declines in key markets, while advancing its Montrose facility project with funding plans underway.